

We investigated the molecular profiling of HR-positive, HER2-negative breast cancers patients treated with NET, and identified Th1-related immune system and lipid metabolism play roles and targeted NGS analysis revealed a high frequency of clinically relevant somatic mutations, particularly in PIK3CA/AKT/mTOR and the cell cycle and apoptosis pathway in endocrine-resistant tumors.

